Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) continues to have
the worst 5-year survival of any malignancy. With 338,000 new cases diagnosed and over …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a
dismal prognosis. While immunotherapy has been deemed a breakthrough treatment for …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is the most common type of
pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading …

Pancreatic ductal adenocarcinoma (PDAC) is the most common and aggressive type of
pancreatic cancer and has abysmal survival rates. In the past two decades …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an
average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have …

The rising incidence and persistent dismal 5-year overall survival of pancreatic ductal
adenocarcinoma (PDAC) highlight the need for new effective systemic therapies …

Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional
treatments, although a limited number of early-stage patients can undergo radical resection …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor with high lethality. Even
with surgery, radiotherapy, chemotherapy, and other locoregional or systemic therapies, the …

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest
cancer in the United States by 2025, with 5-year survival at less than 10%. In other …

Abstract Purpose of Review Despite all efforts, pancreatic ductal adenocarcinoma (PDAC)
remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate …